
TAK
Takeda Pharmaceutical Co Ltd
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
14.720
Open
14.720
VWAP
14.52
Vol
3.64M
Mkt Cap
45.57B
Low
14.410
Amount
52.89M
EV/EBITDA(TTM)
9.89
Total Shares
3.14B
EV
11.84T
EV/OCF(TTM)
12.54
P/S(TTM)
1.51
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research and development, manufacture, sale and licensing of pharmaceuticals. The Company focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The Company focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The Company operates in Japan, the United States, Europe, and China.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q3
FY2026Q2
FY2026Q1
1.18T
+3%
--
--
1.16T
-1.08%
--
--
1.16T
-3.95%
--
--
Estimates Revision
The market is revising Downward the revenue expectations for Takeda Pharmaceutical Company Limited (TAK) for FY2026, with the revenue forecasts being adjusted by -0.37% over the past three months. During the same period, the stock price has changed by -3.35%.
Revenue Estimates for FY2026
Revise Downward

-0.37%
In Past 3 Month
Stock Price
Go Down

-3.35%
In Past 3 Month
1 Analyst Rating

10.88% Upside
Wall Street analysts forecast TAK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TAK is 16.00 USD with a low forecast of 16.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy

10.88% Upside
Current: 14.430

Low
16.00
Averages
16.00
High
16.00

10.88% Upside
Current: 14.430

Low
16.00
Averages
16.00
High
16.00
Needham
Needham
Buy
maintain
$270 -> $300
2025-05-29
Reason
Needham
Needham
Price Target
$270 -> $300
2025-05-29
maintain
Buy
Reason
Needham raised the firm's price target on Veeva (VEEV) to $300 from $270 and keeps a Buy rating on the shares after its Q1 earnings beat and guidance raise. Despite concerns related to Salesforce's (CRM) recent announcement of winning Takeda (TAK) for CRM, Veeva is executing well on the conversion to Vault, with over 200 customers expected to be live by company's summit next spring, the analyst tells investors in a research note. Veeva also believes that custom builds for companies like Takeda may prove too costly, leading the company to see opportunities for competitive win backs, the firm added.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Takeda Pharmaceutical Co Ltd (TAK.N) is 0.00, compared to its 5-year average forward P/E of 27.91. For a more detailed relative valuation and DCF analysis to assess Takeda Pharmaceutical Co Ltd 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
27.91
Current PE
0.00
Overvalued PE
40.60
Undervalued PE
15.23
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair
5Y Average EV/EBITDA
9.39
Current EV/EBITDA
9.31
Overvalued EV/EBITDA
10.55
Undervalued EV/EBITDA
8.23
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair
5Y Average PS
1.61
Current PS
1.50
Overvalued PS
1.77
Undervalued PS
1.45
Financials
Annual
Quarterly
FY2025Q4
YoY :
+0.24%
1.05T
Total Revenue
FY2025Q4
YoY :
-157.31%
-23.67B
Operating Profit
FY2025Q4
YoY :
+3343.49%
-103.10B
Net Income after Tax
FY2025Q4
YoY :
+3301.56%
-65.31
EPS - Diluted
FY2025Q4
YoY :
-50.90%
94.56B
Free Cash Flow
FY2025Q4
YoY :
-12.62%
44.45
Gross Profit Margin - %
FY2025Q4
YoY :
-100.00%
N/A
FCF Margin - %
FY2025Q4
YoY :
+3396.43%
-9.79
Net Margin - %
FY2025Q4
YoY :
-100.00%
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
TAK News & Events
Events Timeline
2025-07-17 (ET)
2025-07-17
11:58:09
Avidity, Phathom mentioned as potential takeout targets at Needham

2025-07-17
08:05:32
Keros Therapeutics announces first patient dosed in Phase 3 RENEW trial

2025-07-14 (ET)
2025-07-14
05:20:56
Takeda announces oveporexton studies met all primary, secondary endpoints

Sign Up For More Events
Sign Up For More Events
News
9.0
07-17NASDAQ.COMKeros To Receive Milestone Payment Under License Agreement With Takeda
5.0
06-25NewsfilterTakeda Announces New Assignments of Directors
9.0
06-03NewsfilterEuropean Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD
Sign Up For More News
People Also Watch

IT
Gartner Inc
355.400
USD
-1.66%

XEL
Xcel Energy Inc
70.380
USD
+1.05%

CCI
Crown Castle Inc
105.140
USD
+0.86%

ODFL
Old Dominion Freight Line Inc
162.090
USD
-0.09%

KVUE
Kenvue Inc
22.000
USD
+0.69%

GEHC
GE Healthcare Technologies Inc
75.960
USD
-0.37%

CTSH
Cognizant Technology Solutions Corp
75.680
USD
+0.16%

NET
Cloudflare Inc
197.350
USD
+3.19%

CPNG
Coupang Inc
31.490
USD
+1.09%

VRSK
Verisk Analytics Inc
301.900
USD
-0.23%
FAQ

What is Takeda Pharmaceutical Co Ltd (TAK) stock price today?
The current price of TAK is 14.43 USD — it has decreased -2.1 % in the last trading day.

What is Takeda Pharmaceutical Co Ltd (TAK)'s business?

What is the price predicton of TAK Stock?

What is Takeda Pharmaceutical Co Ltd (TAK)'s revenue for the last quarter?

What is Takeda Pharmaceutical Co Ltd (TAK)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Takeda Pharmaceutical Co Ltd (TAK)'s fundamentals?

How many employees does Takeda Pharmaceutical Co Ltd (TAK). have?
